TP53 and gastrointestinal stromal tumor: The western blot analysis revealed that adavosertib treatment disrupted cell cycle control in p53 MT GIST cells, leading to increased Wee1 phosphorylation (p-Wee1) and reduced phospho-cdc2 (p-cdc2) expression.